Ask VialBase
cognitive

Cerebrolysin

FDA: not-FDA-approved
Last updated · 2026-04-12

Cerebrolysin is a neuropeptide blend derived from pig brain proteins containing low-molecular-weight peptides and free amino acids that cross the blood-brain barrier. It is used extensively in Europe and Asia for neurodegenerative conditions, traumatic brain injury, and stroke recovery. Randomized controlled trial evidence supports improved clinical outcomes in vascular dementia (PMID: 20656516). Contains growth factors that nourish the brain. Promotes neurogenesis, inhibits apoptosis, and supports synaptic plasticity. Supports neuroprotection, synaptic repair, and reduces glial overactivation. Calms CNS, rebuilds damaged pathways, and helps erase "ghost" pain patterns stored in the brain. Supports hippocampal function and cognitive plasticity. - Brain injury and

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight —
Half-life —
CAS number —
Route —
Where to buy Cerebrolysin →Certified-Pep
02

Research summary

Study Type Year Key Finding
Cerebrolysin for vascular dementia. Cochrane systematic review and meta-analysis of randomised controlled trials 2019 Six randomised controlled trials with 597 participants were eligible; no new studies qualified for this update, meaning no new trial evidence had appeared since the 2013 review
Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis. Systematic review and meta-analysis of retrospective and prospective clinical studies (non-Cochrane) 2023 Ten clinical studies covering 8749 patients were eligible after searching PubMed, CINAHL, Web of Science, and Embase from database inception to 11 July 2022
Cerebrolysin for acute ischaemic stroke. Cochrane systematic review and meta-analysis of randomised controlled trials 2023 Seven RCTs with 1773 participants met inclusion criteria; moderate-certainty evidence indicates Cerebrolysin or Cortexin probably result in little to no difference in all-cause death (RR 0.96, 95% CI 0.65 to 1.41; 6 trials, 1689 participants)
Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis. Systematic review and meta-analysis of clinical trials (non-Cochrane) 2023 First meta-analysis to isolate the subarachnoid hemorrhage (SAH) subpopulation; the authors note no prior meta-analysis existed for SAH patients specifically

Stacks containing Cerebrolysin

Brain Blitz

Semax + Dihexa + Cerebrolysin

Executive Function

Semax + Cerebrolysin + Selank

28-day resets featuring Cerebrolysin

03

Sourcing

Current prices

Updated today

60mg

Only vendor stocking this size on the VialBase roster.

Stocks this compound Third-party tested Public COAs

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • CMP
  • CBC
  • CRP
DURING CYCLE
  • CMP
  • CRP
POST-CYCLE
  • CMP
  • CBC
Safety & Regulatory Status
FDA STATUS not-FDA-approved

Regulatory status for Cerebrolysin may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.

Frequently Asked Questions

What is Cerebrolysin?
Cerebrolysin is a neuropeptide blend derived from pig brain proteins containing low-molecular-weight peptides and free amino acids that cross the blood-brain barrier. It is used extensively in Europe and Asia for neurodegenerative conditions, traumatic brain injury, and stroke recovery.
How does Cerebrolysin work?
Contains growth factors that nourish the brain. Promotes neurogenesis, inhibits apoptosis, and supports synaptic plasticity. Supports neuroprotection, synaptic repair, and reduces glial overactivation.
How is Cerebrolysin dosed?
Standard: 5 ml IM daily or every other day (most common); Cycle: 10-20 days; up to 30 days for TBI; Maintenance: 5 ml IM 2x/week; Route: Intramuscular (IM) injection; IV also used clinically. These figures reflect commonly cited research protocols, not medical advice — consult a clinician.
Is Cerebrolysin FDA-approved?
Cerebrolysin is not FDA-approved. Not FDA-approved in the United States; Widely studied and used internationally — approved in many countries outside the US; Approved in Russia and Eastern Europe for clinical use; Available through international pharmacies and research suppliers.

References

  1. Cui S, Chen N, Yang M, et al.. Cerebrolysin for vascular dementia.. The Cochrane database of systematic reviews (2019). PMID: 31710397
  2. Jarosz K, Kojder K, Andrzejewska A, et al.. Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis.. Brain sciences (2023). PMID: 36979317
  3. Ziganshina LE, Abakumova T, Nurkhametova D, et al.. Cerebrolysin for acute ischaemic stroke.. The Cochrane database of systematic reviews (2023). PMID: 37818733
  4. Kojder K, Jarosz K, Bosiacki M, et al.. Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.. Journal of clinical medicine (2023). PMID: 37892776